Essential CNS Drug Development

Edited by

Amir Kalali
Vice President, Medical and Scientific Services, and Global Therapeutic Team Leader (CNS) at Quintiles Inc, and Professor of Psychiatry at the University of California San Diego, San Diego, CA, USA

Sheldon Preskorn
Professor of Psychiatry, Kansas University School of Medicine-Wichita (KUSM-W), and Chief Science Officer, KUSM-W Clinical Trial Unit, Wichita, KS, USA

Joseph Kwentus
Clinical Professor at the University of Mississippi Medical Center, Jackson, MS, USA

Stephen M. Stahl
Adjunct Professor of Psychiatry at the University of California San Diego, San Diego, CA, USA, and Honorary Senior Visiting Fellow at the University of Cambridge, UK

CAMBRIDGE UNIVERSITY PRESS
## Contents

**List of contributors**  vi
**Preface**  ix

1. **History of CNS drug development**  1  Sheldon Preskorn

2. **Regulatory issues**  14  Gwen L. Zornberg

3. **Essential CNS drug development – pre-clinical development**  31  Alan J. Cross and Frank D. Yocca

4. **Phase I trials: from traditional to newer approaches**  55  Matthew Macaluso, Michael Krams, and Sheldon Preskorn

5. **Phase II development and the path to personalized medicine in CNS disease**  70  Douglas E. Feltner and Kenneth R. Evans

6. **CNS drug development – Phase III**  92  Judith Dunn, Penny Randall, and Amir Kalali

7. **Statistics issues relevant to CNS drug development**  100  Craig H. Mallinckrodt, William R. Prucka, and Geert Molenberghs

8. **Clinical trials management at company level**  127  Nuala Murphy

9. **Clinical trials management at the site level**  148  Joseph Kwentus

10. **Medical writing for CNS indications**  156  Ginette Nachman

11. **Dissemination of clinical trial information: multiple audiences, multiple formats**  169  Leslie Citrome

12. **The importance of treating cognition in schizophrenia and other severe mental illnesses: background, strategies, and findings to date**  177  Philip D. Harvey and Richard S. E. Keefe

13. **Leveraging disruptive technologies to drive innovation in CNS clinical drug development**  192  Penny Randall, Judith Dunn, and Amir Kalali

**Index**  200

*Color plates found between pages 118 and 119.*